Dynamic and Adaptable Infrastructure for Drug Development and Outreach to Aid the Research Community in Advancing Medication Repurposing and Repositioning Efforts for Substance Use Disorders (SUDs) (U54 - Clinical Trials Not Allowed)
Department of Health and Human Services
Description
- Sponsor: National Institute on Drug Abuse (NIDA), NIH
- Goal: Fund a Center that helps academic and biotech teams repurpose or reposition existing drugs into treatments for substance use disorders (SUDs), speeding development, lowering costs, and improving chances of success.
- Why this matters: There is major unmet need in SUDs and limited pharma investment. Evidence suggests some already-approved medicines (for example, GLP‑1 drugs like exenatide, semaglutide, liragluti…
The National Institute on Drug Abuse (NIDA) supports biomedical innovation through a variety of funding mechanisms. Strategic approaches such as drug repurposing and repositioning can accelerate this process by shortening development timelines, lowering costs, and improving success rates compare…
Source
Grant ID
RFA:RFA-DA-26-020.html
Agency
Department of Health and Human Services
Similar opportunities
- Dynamic and Adaptable Infrastructure for Drug Development and Outreach to Aid the Research Community in Advancing Medication Repurposing and Repositioning Efforts for Substance Use Disorders (SUDs) (U54 - Clinical Trials Not Allowed)
Department of Health and Human Services
- Dynamic and Adaptable Infrastructure for Drug Development and Outreach to Aid the Research Community in Advancing Medication Repurposing and Repositioning Efforts for substance use disorders (SUDs) (U54 - Clinical Trials Not Allowed)
Department of Health and Human Services
- Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
Department of Health and Human Services
- Notice of Special Interest (NOSI): HEAL Initiative: Grand Opportunity in Medications Development for Substance-Use Disorders
National Institutes of Health
- Collaborations to Enhance Drug Development and Regulatory Science
Department of Health and Human Services